Quality Improvement Initiatives to Assess and Improve PET/CT Injection Infiltration Rates at Multiple Centers

PET/CT radiotracer infiltration is not uncommon and is often outside the imaging field of view. Infiltration can negatively affect image quality, image quantification, and patient management. Until recently, there has not been a simple way to routinely practice PET radiopharmaceutical administration quality control and quality assurance. Our objectives were to quantify infiltration rates, determine associative factors for infiltration, and assess whether rates could be reduced at multiple centers and then sustained. Methods: A “design, measure, analyze, improve, and control” quality improvement methodology requiring novel technology was used to try to improve PET/CT injection quality. Teams were educated on the importance of quality injections. Baseline infiltration rates were measured, center-specific associative factors were analyzed, team meetings were held, improvement plans were established and executed, and rates remeasured. To ensure that injection-quality gains were retained, real-time feedback and ongoing monitoring were used. Sustainability was assessed. Results: Seven centers and 56 technologists provided data on 5,541 injections. The centers’ aggregated baseline infiltration rate was 6.2% (range, 2%–16%). On the basis of their specific associative factors, 4 centers developed improvement plans and reduced their aggregated infiltration rate from 8.9% to 4.6% (P < 0.0001). Ongoing injection monitoring showed sustainability. Significant variation was found in center- and technologist-level infiltration rates (P < 0.0001 and P = 0.0020, respectively). Conclusion: A quality improvement approach with new technology can help centers measure infiltration rates, determine associative factors, implement interventions, and improve and sustain injection quality. Because PET/CT images help guide patient management, the monitoring and improvement of radiotracer injection quality are important.

[1]  Sarah A. Frye,et al.  Usefulness of Topically Applied Sensors to Assess the Quality of 18F-FDG Injections and Validation Against Dynamic Positron Emission Tomography (PET) Images , 2018, Front. Med..

[2]  J. Crowley,et al.  Impact of an 18F-FDG PET/CT Radiotracer Injection Infiltration on Patient Management—A Case Report , 2018, Front. Med..

[3]  D. Berman,et al.  Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC , 2017, The Journal of Nuclear Medicine.

[4]  D. Townsend,et al.  The Importance of Quality Control for Clinical PET Imaging , 2017, The Journal of Nuclear Medicine Technology.

[5]  Sarah A. Frye,et al.  Novel Method to Detect and Characterize 18F-FDG Infiltration at the Injection Site: A Single-Institution Experience , 2017, The Journal of Nuclear Medicine Technology.

[6]  Yan Liu,et al.  Guidelines for quality control of PET/CT scans in a multicenter clinical study , 2017, EJNMMI Physics.

[7]  C. West,et al.  Chemotherapy Extravasation: Establishing a national benchmark for incidence among cancer centers , 2017, Clinical journal of oncology nursing.

[8]  T. Ruddy,et al.  False-positive stress PET–CT imaging in a patient with interstitial injection , 2017, Journal of Nuclear Cardiology.

[9]  D. Mankoff,et al.  Making Molecular Imaging a Clinical Tool for Precision Oncology: A Review , 2017, JAMA oncology.

[10]  Sudheer D. Rani,et al.  Towards real-time topical detection and characterization of FDG dose infiltration prior to PET imaging , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Koen Van Laere,et al.  SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0 , 2016, The Journal of Nuclear Medicine.

[12]  Tomio Inoue,et al.  Fever of unknown origin (FUO): evaluation of 50 cases with 18F-FDG PET/CT. , 2015 .

[13]  Ion Codreanu,et al.  Growing applications of FDG PET-CT imaging in non-oncologic conditions , 2015, Journal of biomedical research.

[14]  M. Bhargavan-Chatfield,et al.  Intravenous contrast extravasation during CT: a national data registry and practice quality improvement initiative. , 2015, Journal of the American College of Radiology : JACR.

[15]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  J. Mosquera,et al.  Correction for FDG PET dose extravasations: Monte Carlo validation and quantitative evaluation of patient studies. , 2014, Medical physics.

[17]  Yiyan Liu Fluorodeoxyglucose uptake in absence of CT abnormality on PET-CT: What is it? , 2013, World journal of radiology.

[18]  B. Sanghera,et al.  FDG injection site extravasation: potential pitfall of misinterpretation and missing metastases. , 2012, Clinical nuclear medicine.

[19]  A. Bhattacharya,et al.  New axillary lymph nodal F-18 fluoro-deoxy glucose uptake in an interim positron emission tomography scan – not always a sign of disease progression , 2011, Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India.

[20]  Hyunsuk Shim,et al.  Metabolic positron emission tomography imaging in cancer detection and therapy response. , 2011, Seminars in oncology.

[21]  F. S. Chew Extravasation of iodinated contrast medium during CT: self-assessment module. , 2010, AJR. American journal of roentgenology.

[22]  R. Boellaard Standards for PET Image Acquisition and Quantitative Data Analysis , 2009, Journal of Nuclear Medicine.

[23]  M. Osman,et al.  FDG manual injection verses infusion system: A comparison of dose precision and extravasation , 2009 .

[24]  M. Osman,et al.  Contamination in 18F-FDG PET/CT: An initial experience , 2009 .

[25]  M. Osman,et al.  FDG Dose Extravasations in PET/CT: Frequency and Impact on SUV Measurements , 2007, Front. Oncol..

[26]  Steven Burrell,et al.  Artifacts and pitfalls in myocardial perfusion imaging. , 2006, Journal of nuclear medicine technology.

[27]  V. Lowe,et al.  Normal variants and pitfalls in whole-body PET imaging with 18F FDG , 2006, Applied Radiology.

[28]  G. Denardo Editorial: "right place, wrong place": extravasation of therapeutic drug for molecular targeted radiotherapy. , 2006, Cancer biotherapy & radiopharmaceuticals.

[29]  M. Knopp,et al.  Impact of FDG extravasation on SUV measurements in clinical PET/CT. Should we routinely scan the injection site? , 2006 .

[30]  V. Ambrosini,et al.  Focal lung uptake of 18F-fluorodeoxyglucose (18F-FDG) without computed tomography findings , 2005, Nuclear medicine communications.

[31]  Wolfgang A Weber,et al.  Use of PET for monitoring cancer therapy and for predicting outcome. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  Thomas Beyer,et al.  Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Alavi,et al.  Potential false-positive FDG PET imaging caused by subcutaneous radiotracer infiltration. , 2003, Clinical nuclear medicine.

[34]  D. Binns,et al.  Inadvertent 2-deoxy-2-[18F]fluoro-D-glucose lymphoscintigraphy: a potential pitfall characterized by hybrid PET-CT. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[35]  M. Spieth,et al.  A tabulated summary of the FDG PET literature. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  K. Rezai,et al.  Incidental Lymph Node Visualization on Bone Scan Due to Subcutaneous Infiltration of Tc‐99m MDP A Potential for False Positive Interpretation , 1993, Clinical nuclear medicine.

[37]  R. Wahl,et al.  99Tcm-MDP uptake by lymph nodes following tracer infiltration: clinical and laboratory evaluation , 1987, Nuclear medicine communications.

[38]  H. Shim,et al.  Metabolic PET Imaging in Cancer Detection and Therapy Response , 2011 .

[39]  The Role of PET / CT in Radiation Treatment Planning for Cancer Patient Treatment , 2008 .

[40]  C. Engelking,et al.  Vesicant extravasation: myths and realities. , 1995, Oncology nursing forum.